Loading clinical trials...
Loading clinical trials...
The primary objectives of the study are to determine the safety of high-dose aflibercept (hereafter referred to as HD) and to determine if HD provides greater intraocular pharmacodynamic (PD) effect a...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Regeneron Pharmaceuticals
Collaborators
NCT06346600 · Neovascular (Wet) Age-related Macular Degeneration
NCT07567898 · Diabetic Macular Edema, Neovascular (Wet) Age-Related Macular Degeneration, and more
NCT05439629 · Neovascular (Wet) Age-related Macular Degeneration
NCT04847895 · Neovascular (Wet) Age-related Macular Degeneration
Regeneron Study Site
Phoenix, Arizona
Regeneron Study Site
Sun City, Arizona
Regeneron Study Site
Encino, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions